Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together, Roche and Spark will be able to significantly improve the live...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news
Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together, Roche and Spark will be able to significantly improve the live...
Source: Roche Investor Update - December 17, 2019 Category: Pharmaceuticals Source Type: news
Roche purchases shares in tender offer for Spark Therapeutics, Inc.
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh. The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of approximately 23,276...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news
Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 201...
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news
Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purcha...
Source: Roche Investor Update - December 16, 2019 Category: Pharmaceuticals Source Type: news
Highmark Establishes High-Performance Hemophilia Partnership
Highmark announced a new partnership focused on the treatment and management of hemophilia, which aims to ensure that members receive hemophilia drugs from organizations that meet rigorous performance...(PRWeb November 19, 2019)Read the full story at https://www.prweb.com/releases/highmark_establishes_high_performance_hemophilia_partnership/prweb16725465.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2019 Category: Pharmaceuticals Source Type: news
Putting a Price on Life: Is the Answer Outside Pharma?
To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment. Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400. Another example of early innovation is Neovasculgen (...
Source: EyeForPharma - November 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 10, 2019 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news
1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
TUESDAY, Sept. 10, 2019 -- The expected number of patients with hemophilia worldwide is 1,125,000 male patients, with 418,000 severe cases, according to research published online Sept. 10 in the Annals of Internal Medicine.
Alfonso Iorio, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2019 Category: Pharmaceuticals Source Type: news
Hemophilia disease 3 times more prevalent than previously thought, study finds
In a new study published Monday, researchers at Hamilton's McMaster University say more than 1,125,000 men around the world have hemophilia, and 418,000 of those have a severe version of the mostly undiagnosed disease. (Source: CBC | Health)
Source: CBC | Health - September 9, 2019 Category: Consumer Health News Tags: News/Canada/Hamilton Source Type: news
NHS to fund 'life changing' haemophilia drug
Emicizumab mimics the action of factor VIII to stem uncontrolled bleeds Related items fromOnMedica Child health should be election priority say experts and public Government launches its Child Health Strategy Cash-injection for sick children UK lagging behind other comparable countries on young people ’s health England falling behind on child health (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 21, 2019 Category: UK Health Source Type: news
'Trailblazing' treatment that prevents bleeds in haemophiliacs will be available on NHS England
Emicizumab, which mimics the missing protein, can be injected under the skin as little as every two weeks. It is now available after NHS England agreed to fund the drug, sold under the brand name Hemlibra. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2019 Category: Consumer Health News Source Type: news
New drug for people who can bleed uncontrollably
NHS England is funding a new treatment for patients with severe haemophilia A. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 21, 2019 Category: Consumer Health News Source Type: news
Life-changing drug to stop deadly bleeding available on the NHS
NHS England is to fund a life-changing treatment for thousands of people with severe haemophilia, which will dramatically cut their risk of life-threatening bleeds and reduce treatment time. (Source: NHS Networks)
Source: NHS Networks - August 20, 2019 Category: UK Health Source Type: news
Bayer recalls two lots of mislabeled hemophilia A med
The drugmaker is voluntarily recalling two lots that were filled with factor VIII hemophilia A treatment Jivi but were labeled as containing hemophilia treatment Kogenate FS (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 23, 2019 Category: Pharmaceuticals Source Type: news
